Home > Research > Publications & Outputs > Death rattle: an audit of hyoscine (scopolamine...

Research

Links

Text available via DOI:

Keywords

View graph of relations

Death rattle: an audit of hyoscine (scopolamine) use and review of management.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Death rattle: an audit of hyoscine (scopolamine) use and review of management. / Bennett, Michael I.
In: Journal of Pain and Symptom Management, Vol. 12, No. 4, 10.1996, p. 229-233.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Bennett, MI 1996, 'Death rattle: an audit of hyoscine (scopolamine) use and review of management.', Journal of Pain and Symptom Management, vol. 12, no. 4, pp. 229-233. https://doi.org/10.1016/0885-3924(96)00151-0

APA

Bennett, M. I. (1996). Death rattle: an audit of hyoscine (scopolamine) use and review of management. Journal of Pain and Symptom Management, 12(4), 229-233. https://doi.org/10.1016/0885-3924(96)00151-0

Vancouver

Bennett MI. Death rattle: an audit of hyoscine (scopolamine) use and review of management. Journal of Pain and Symptom Management. 1996 Oct;12(4):229-233. doi: 10.1016/0885-3924(96)00151-0

Author

Bennett, Michael I. / Death rattle: an audit of hyoscine (scopolamine) use and review of management. In: Journal of Pain and Symptom Management. 1996 ; Vol. 12, No. 4. pp. 229-233.

Bibtex

@article{6d19402b8b5f47adb2be92a9201afcaa,
title = "Death rattle: an audit of hyoscine (scopolamine) use and review of management.",
abstract = "This study investigated the pattern and determinants of hyoscine (scopolamine) use for death rattle by a retrospective analysis of 100 consecutive deaths in a 22-bed hospice. Patient diagnoses, duration of stay, and doses and route of administration of hyoscine used in the final 48 hr before death were recorded. One-half of the patients received hyoscine in some form during the final 24 hr before death. Patients who were in the hospice for longer than 9 days and those with cerebral malignancy were given the highest doses of hyoscine in the final 24 hr (z = -2.558, P = 0.011, and z = -1.968, P = 0.048, respectively). Response to hyoscine appears to be variable, and a distinction is proposed between death while due to salivary secretions (type 1) and that due to bronchial secretions (type 2) to explain the observed patterns of use. It is likely that hyoscine is more efficacious in treating type 1 death rattle than it is in treating type 2 death rattle.",
keywords = "Hyoscine, scopolamine, death rattle, respiratory secretions, symptom controll, halliative care",
author = "Bennett, {Michael I.}",
year = "1996",
month = oct,
doi = "10.1016/0885-3924(96)00151-0",
language = "English",
volume = "12",
pages = "229--233",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Death rattle: an audit of hyoscine (scopolamine) use and review of management.

AU - Bennett, Michael I.

PY - 1996/10

Y1 - 1996/10

N2 - This study investigated the pattern and determinants of hyoscine (scopolamine) use for death rattle by a retrospective analysis of 100 consecutive deaths in a 22-bed hospice. Patient diagnoses, duration of stay, and doses and route of administration of hyoscine used in the final 48 hr before death were recorded. One-half of the patients received hyoscine in some form during the final 24 hr before death. Patients who were in the hospice for longer than 9 days and those with cerebral malignancy were given the highest doses of hyoscine in the final 24 hr (z = -2.558, P = 0.011, and z = -1.968, P = 0.048, respectively). Response to hyoscine appears to be variable, and a distinction is proposed between death while due to salivary secretions (type 1) and that due to bronchial secretions (type 2) to explain the observed patterns of use. It is likely that hyoscine is more efficacious in treating type 1 death rattle than it is in treating type 2 death rattle.

AB - This study investigated the pattern and determinants of hyoscine (scopolamine) use for death rattle by a retrospective analysis of 100 consecutive deaths in a 22-bed hospice. Patient diagnoses, duration of stay, and doses and route of administration of hyoscine used in the final 48 hr before death were recorded. One-half of the patients received hyoscine in some form during the final 24 hr before death. Patients who were in the hospice for longer than 9 days and those with cerebral malignancy were given the highest doses of hyoscine in the final 24 hr (z = -2.558, P = 0.011, and z = -1.968, P = 0.048, respectively). Response to hyoscine appears to be variable, and a distinction is proposed between death while due to salivary secretions (type 1) and that due to bronchial secretions (type 2) to explain the observed patterns of use. It is likely that hyoscine is more efficacious in treating type 1 death rattle than it is in treating type 2 death rattle.

KW - Hyoscine

KW - scopolamine

KW - death rattle

KW - respiratory secretions

KW - symptom controll

KW - halliative care

U2 - 10.1016/0885-3924(96)00151-0

DO - 10.1016/0885-3924(96)00151-0

M3 - Journal article

VL - 12

SP - 229

EP - 233

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 4

ER -